Monitoring EGFR -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Felip, Eudald (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Bosch-Barrera, J (Hospital Universitari de Girona Doctor Josep Trueta)
de Aguirre, Itziar (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Ramirez, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Mesia, Carles (Institut Català d'Oncologia)
Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Roa, Diana (Hospital Universitari de Girona Doctor Josep Trueta)
Sais, Elia (Hospital Universitari de Girona Doctor Josep Trueta)
García García, Yolanda (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Blanco, Remei (Consorci Sanitari de Terrassa. Departament d'Oncologia)
Sanchez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Villacorta, Claudia Rosa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Queralt, C. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Velarde, Jose María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Universitat Autònoma de Barcelona

Data:	2018
Resum:	Osimertinib is efficacious in lung cancer patients with epidermal growth factor receptor (EGFR) mutations and acquired resistance (AR) to EGFR tyrosine kinase inhibitors due to EGFR -T790M mutation (T790M). We sought to describe T790M changes in serum/plasma during osimertinib therapy and correlate these changes with treatment outcomes. Serum/plasma from EGFR -mutant lung cancer patients with T790M-AR was collected before and during osimertinib treatment. Changes in T790M were evaluated using a peptide-nucleic acid-PCR assay, and correlated with clinical and radiographic response. Thirteen patients were included. Median time on osimertinib treatment was 10. 6 months with a median progression-free survival of 13. 6 months. Best response to osimertinib was partial response (PR), stable disease (SD) or progression (PD) in 46. 1%, 30. 8% and 23. 1% of patients, respectively. Most of the patients were paucisymptomatic at baseline. Symptom improvement was reported in 66. 6% of responder patients; while symptoms remained stable in 75% of patients with SD, and 66% of patients with PD had clinical deterioration. Three patterns of T790M changes during osimertinib treatment were identified. T790 remained detectable with PD or a short-lasting SD in 15. 4% of the patients. T790M disappeared in 69. 2% of patients with PR or SD. T790M disappeared, despite clinical and/or radiographic progression in 15. 4% of the patients. Changes of T790M in serum/plasma in EGFR -mutant lung cancer patients with T790M-AR might be a useful marker of symptomatic and radiographic outcome to osimertinib. Longer follow-up is needed to establish if subsequent emergence of T790M could be a marker of resistance.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	EGFR-T790M mutation ; Serum/plasma ; Osimertinib ; Acquired resistance ; EGFR tyrosine kinase inhibitors
Publicat a:	Oncotarget, Vol. 9 (june 2018) , p. 27074-27086, ISSN 1949-2553

DOI: 10.18632/oncotarget.25478
PMID: 29930751

13 p, 2.2 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d’Investigació i Innovació Parc Taulí (I3PT)
Articles > Articles de recerca
Articles > Articles publicats